Literature DB >> 9796062

Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.

I Jabbal-Gill1, A N Fisher, R Rappuoli, S S Davis, L Illum.   

Abstract

Mice were intranasally immunised with a mixture of Bordetella pertussis filamentous haemagglutinin (FHA) and recombinant pertussis toxin, PT-9K/129G (rPT) in combination with chitosan. For both antigens, this formulation induced systemic responses as measured by serum IgG and also mucosal responses as measured by secretory IgA in lung lavage and nasal washes. Immunosorbant assays were used to measure these responses. Both the systemic and mucosal responses were considerably higher than those produced when a mixture of rPT and FHA was administered nasally without chitosan. In comparison, intraperitoneally administered rPT/FHA adsorbed to Alhydrogel elicited only a systemic response, and nasal chitosan solution produced neither systemic nor mucosal response. This study clearly demonstrated that chitosan potentiated the serum and mucosal immune responses to nasally administered FHA and rPT in mice. Hence, this nasal chitosan delivery system has potential as a new non-injectable vaccine for the prophylaxis of whooping cough.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796062     DOI: 10.1016/s0264-410x(98)00077-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 3.  Chitosan and its use as a pharmaceutical excipient.

Authors:  L Illum
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

4.  Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.

Authors:  M Watanabe; M Nagai
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Chitosan enhances nanoparticle delivery from the reproductive tract to target draining lymphoid organs.

Authors:  Jaehyung Park; Renuka Ramanathan; Linhchi Pham; Kim A Woodrow
Journal:  Nanomedicine       Date:  2017-04-20       Impact factor: 5.307

6.  Role of systemic and mucosal immune responses in reciprocal protection against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.

Authors:  Mineo Watanabe; Masaaki Nagai
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

Review 7.  Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review.

Authors:  Mohammad Ariful Islam; Jannatul Firdous; Yun-Jaie Choi; Cheol-Heui Yun; Chong-Su Cho
Journal:  Int J Nanomedicine       Date:  2012-12-13

8.  Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine.

Authors:  Kai Zhao; Yang Zhang; Xiaoyan Zhang; Ci Shi; Xin Wang; Xiaohua Wang; Zheng Jin; Shangjin Cui
Journal:  Int J Nanomedicine       Date:  2014-09-30

Review 9.  Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.

Authors:  Dan Zheng; Yinglei Yi; Ze Chen
Journal:  Viruses       Date:  2012-12-10       Impact factor: 5.048

10.  Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.

Authors:  Violaine Dubois; Camille Locht
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.